Αρχική World News FDA Approves Durvalumab for Muscle Invasive Bladder Cancer World News FDA Approves Durvalumab for Muscle Invasive Bladder Cancer Από Ogkologos - 2 Μαΐου, 2025 931 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the NIAGARA study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Motivational Speaker Shares Her 11-Year Battle With Breast Cancer In New... 16 Νοεμβρίου, 2021 Temporary Interruption of Adjuvant Endocrine Treatment to Attempt Pregnancy Does Not... 8 Μαΐου, 2023 ΠΟΝΟΣ 8 Μαρτίου, 2019 A Large Case-Control Study of Hodgkin Lymphoma Survivors Suggests a Dose-Response... 16 Φεβρουαρίου, 2023 Φόρτωση περισσοτέρων HOT NEWS A coming together of minds for early detection Doctors Think Woman Has A Brain Tumor, But Then They Open... Avelumab Ineffective in Patients with MSS Endometrial Cancer Carrying TP53 Mutation ESMO Welcomes EU Proposals for MFF & FP10 and Calls for...